NCT00395551View on ClinicalTrials.gov

Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Choroidal Neovascularization

Interventions

DRUG

ranibizumab

0.5mg intravitreal injection

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Ophthalmic Consultants of Boston

OTHER